Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications.
Immunotherapy
; 8(12): 1427-1436, 2016 12.
Article
em En
| MEDLINE
| ID: mdl-27737604
ABSTRACT
Biologics are increasingly being used to modify the course of immune-mediated inflammatory diseases. Some main agents are monoclonal antibodies and a fusion-protein that target TNF. This group includes adalimumab, infliximab, certolizumab pegol, golimumab and etanercept. Although the efficacy of anti-TNFs is supported by numerous randomized clinical trials, their pharmacokinetics depend on many factors, in particular immunogenicity, which can cause marked and rapid clearance and a consequent decrease in efficacy. Kinetics involve receptors that recognize the Fc fragment of the antibody and are responsible for various processes. Pharmacological advances permit optimizing the pharmacokinetics of anti-TNFs. In this review, we examine the kinetics of anti-TNF biologics, and consequent therapeutic implications, and overview some latest developments in the field. First draftsubmitted 17 May 2016; Accepted for publication 15 September2016; Published online 14 October 2016.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Produtos Biológicos
/
Fator de Necrose Tumoral alfa
/
Doenças do Sistema Imunitário
/
Imunoterapia
/
Inflamação
/
Anti-Inflamatórios
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Immunotherapy
Ano de publicação:
2016
Tipo de documento:
Article